Lubrizol Life Science Health (LLS), a Berkshire Hathaway Company, has introduced its ASTAGILE microcapsules, its new sustainable, organic-certified, astaxanthin (Haematococcus pluvialis), microencapsulated with spirulina, it was reported on Wednesday.
Both ingredients have been combined in a patent-pending product aimed to promote mental agility and support healthy ageing for young and senior adults.
Astaxanthin is a carotenoid found in freshwater microalgae, while spirulina is a type of algae. In order to create the synergistic algae blend, LLS Health collaborated with Neoalgae Micro Seaweeds Products, SL, a research and development company in Spain dedicated to microalgae biotechnology. LLS claims that recent studies showed the cognitive enhancement effects of ASTAGILE, including a boost in memory performance, cognition and learning capabilities, and provided antioxidant and anti-inflammatory protection to the brain.
Novartis to acquire PI3K-alpha inhibitor program from Synnovation in deal worth up to USD3bn
Humacyte prices USD20m registered direct offering
Curia expands Glasgow manufacturing capacity and enhances CLD platform
Congruence Therapeutics secures USD39.5m financing
Pfizer reports Phase 3 TALAPRO-3 results showing improved outcomes in metastatic prostate cancer
Mabtech partners with Sai Life Sciences to expand access to EYRA multiplex immunology platform
Mirecule expands collaboration with Sanofi to advance FSHD therapy
Sanofi's venglustat receives FDA Breakthrough Therapy designation for type 3 Gaucher disease
Alebund Pharmaceuticals signs licensing and equity agreements with R1 Therapeutics
Apertura Gene Therapy agrees manufacturing collaboration with Viralgen
Humacyte submits Israel MAA for Symvess arterial trauma repair
Sentynl Therapeutics and PRG S&T enter licensing agreement for potential HGPS treatment